Succession Planning in Life Sciences: Your Most Overlooked Risk Management Tool

1. Why succession planning matters
Life-sciences organizations depend on specialized knowledge and relatively small pools of scientific, regulatory, manufacturing, and commercial talent. A vacancy in a critical role can delay trials, filings, product launches, or compliance decisions.
The risks of poor planning:
Loss of institutional and scientific knowledge
Delayed regulatory submissions or inspections
Disruption to clinical or manufacturing programs
Increased dependence on external executive searches
Reduced investor, employee, and partner confidence
Loss of intellectual property or critical relationships
An organisation needs to distinguish between emergency succession—what happens if a leader suddenly leaves—and strategic succession—developing the capabilities the organization will need over the next three to five years.
2. When should companies do it?
The central answer is: continuously, with formal reviews at least annually. Succession should not begin only when a CEO announces retirement or a key executive resigns. Boards should keep it on the agenda, including when a new CEO is appointed.
A useful planning horizon is:
Immediate: Who could assume the role tomorrow or within 30 days?
One year: Who could be ready with targeted development?
Three years: What capabilities and leaders must be developed?
Five years: What leadership profile will support the company’s strategy, pipeline, and growth plans?
https://www.pharmexec.com/view/succession-planning-its-not-just-human-resources
Trigger an additional review before major events such as:
A clinical readout or pivotal trial
Regulatory submission or approval
Product launch
Manufacturing expansion
M&A, licensing, or restructuring
A major financing or IPO
Rapid international expansion
A founder, CEO, or technical expert approaching retirement
3. How to build the plan
A practical framework would include the following steps:
Identify mission-critical roles. Go beyond the executive team. Consider heads of clinical operations, regulatory affairs, pharmacovigilance, quality, manufacturing, supply chain, medical affairs, data science, and business development.
https://www.persolindia.com/articles/pharma-succession-planning-talent-pipeline
Assess business impact. Rank roles according to the consequences of vacancy, including regulatory, patient-safety, operational, financial, and intellectual-property risks.
Define future requirements. Assess successors against the organization’s future strategy—not merely the current job description. A successor for a pre-commercial biotech may need different capabilities from one for a global commercial pharmaceutical company.
Evaluate candidates objectively. Use defined competencies, performance evidence, structured assessments, 360-degree feedback, and readiness evaluations rather than visibility, tenure, or personal sponsorship alone.
Create readiness categories. Classify candidates as ready now, ready in one to two years, or longer-term potential. Maintain at least one alternative for every critical position and consider external candidates where internal capability is insufficient.
Develop successors deliberately. Use mentoring, cross-functional assignments, temporary leadership roles, participation in regulatory interactions, board exposure, and responsibility for strategic programs. In life sciences, knowledge transfer should include scientific rationale, regulatory history, quality systems, stakeholder relationships, and decision-making context.
Document emergency arrangements. Specify interim authority, decision rights, communications, delegated responsibilities, and the information required to keep trials, manufacturing, safety reporting, or regulatory work moving.
Review and measure the plan. Useful metrics include time to fill critical roles, proportion of critical positions with ready successors, internal promotion rates, retention of high-potential employees, diversity of the succession pipeline, and performance after promotion.
4. Who should own it?
The board should oversee CEO and executive succession, while the CEO, HR, business-unit leaders, and functional heads should own the wider talent pipeline. Succession planning should also involve leaders of strategic programs and business development rather than being left entirely to HR.
That governance point is especially important in life sciences because the people who understand clinical, regulatory, manufacturing, and technical risk may not sit within the HR function.
5. Food for thought
Succession planning in the life sciences industry is no longer a “nice to have” HR process—it’s a core element of risk management and business continuity. Unplanned leadership gaps can delay clinical trials, regulatory submissions, manufacturing, and product launches, directly impacting patients and revenue. In this article, we explore when, why and how life sciences organisations should approach leadership succession, the mission‑critical roles to prioritise, and practical steps CEOs, HR Directors and Talent Acquisition leaders can take to build a robust leadership pipeline. If your company couldn’t confidently say who would step into each critical role tomorrow, this piece will show you how to close that gap—before it becomes a crisis.
Start the conversation before the transition becomes urgent.
Contact Sharon Shields to discuss how we can help you build a resilient leadership pipeline for the future.


Comments